Javascript must be enabled to continue!
Independent Directors in Asia. A Historical, Contextual and Comparative Approach. Ed. by Dan W. Puchniak, Harald Baum and Luke Nottage.
View through CrossRef
Independent Directors in Asia. A Historical, Contextual and Comparative Approach. Ed. by Dan W. Puchniak, Harald Baum and Luke Nottage. – Cambridge: University Press 2017. XV, 619 pp. (International Corporate Law and Financial Market Regulation.)Independent Directors in Asia. A Historical, Contextual and Comparative Approach. Ed. by Dan W. Puchniak, Harald Baum and Luke Nottage. – Cambridge: University Press 2017. XV, 619 pp. (International Corporate Law and Financial Market Regulation.)
Title: Independent Directors in Asia. A Historical, Contextual and Comparative Approach. Ed. by Dan W. Puchniak, Harald Baum and Luke Nottage.
Description:
Independent Directors in Asia.
A Historical, Contextual and Comparative Approach.
Ed.
by Dan W.
Puchniak, Harald Baum and Luke Nottage.
– Cambridge: University Press 2017.
XV, 619 pp.
(International Corporate Law and Financial Market Regulation.
)Independent Directors in Asia.
A Historical, Contextual and Comparative Approach.
Ed.
by Dan W.
Puchniak, Harald Baum and Luke Nottage.
– Cambridge: University Press 2017.
XV, 619 pp.
(International Corporate Law and Financial Market Regulation.
).
Related Results
Primerjalna književnost na prelomu tisočletja
Primerjalna književnost na prelomu tisočletja
In a comprehensive and at times critical manner, this volume seeks to shed light on the development of events in Western (i.e., European and North American) comparative literature ...
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Efficacy of an Extended Half-Life GlycoPEGylated rFVIII (N8-GP): Pooled Analysis of ABR (Results from Two Clinical Trials)
Abstract
Introduction
The short half-life of standard factor VIII (FVIII) products means that frequent injections (3 to 4 times/week) are needed for e...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...
FAKTOR-FAKTOR YANG MEMPENGARUHI MORTALITAS PADA PASIEN DENGAN FRAKTUR COSTA: Literature Review
FAKTOR-FAKTOR YANG MEMPENGARUHI MORTALITAS PADA PASIEN DENGAN FRAKTUR COSTA: Literature Review
FAKTOR-FAKTOR YANG MEMPENGARUHI MORTALITAS PADA PASIEN DENGAN FRAKTUR COSTA: Literature Review Anna Tri Wahyuni1), Masfuri2), Liya Arista3)1,2,3 Fakultas Ilmu Keperawatan Univers...
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Dynamics of Mutations in Patients with ET Treated with Imetelstat
Abstract
Background: Imetelstat, a first in class specific telomerase inhibitor, induced hematologic responses in all patients (pts) with essential thrombocythemia (...
Plastic Surgery Training and the Problematic Resident
Plastic Surgery Training and the Problematic Resident
Introduction
Plastic surgery resident education is a significant commitment by both programs and residents. Unfortunately, problematic resident behavior may occur and b...
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Combinatorial Antigen Targeting Strategy for Acute Myeloid Leukemia
Introduction: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single leukemia associated antigen with chimeric antigen receptor T (CAR T) cells ...
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Risk of Infections with BCMA-Directed Immunotherapy in Multiple Myeloma
Abstract
Introduction: B cell maturation antigen (BCMA) is a novel target for T cell immunotherapy in MM including bispecific antibody (bsAb) and chimeric antigen re...

